Kuste Biopharma

Develop therapies for unmet medical inflammatory urological diseases

Objective

Develop therapies for unmet medical inflammatory urological diseases such as Interstitial Cystitis/Painful Bladder Syndrome.

Development

Two small molecules acting in the JNK inhibition, have reached up to Phase 3 results.

Press releases

Read more about KUSTE BIOPHARMA in the medias and check our press releases.

Proprietary molecules

10+ years extensively studied, proven safe and efficacious JNK inhibitors for a variety of therapeutic applications.

JNK INHIBITION

Inhibitors of the JNK pathway have a proven therapeutic impact in the treatment of inflammatory diseases.

Launching studies

Launching clinical studies for the unmet clinical need of IC/PBS and preclinical on other inflammatory pathologies e.g. IBD

Discover the team

Governance

Read more about our Scientific Advisory Board and Management Team…

Kuste Biopharma

2 bis rue Tête d’Or
69006 Lyon

+33 (0) 481 133 530
contact@kustebiopharma.com

Logo-kuste-Biopharma-Vertical-desktop
Retour haut de page